FDA Approves Merck ’s Dificid (fidaxomicin) to Treat Clostridioides difficile in Children Aged Six Months and Older

KENILWORTH, N.J.--(BUSINESS WIRE)-- Monday, January 27, 2020 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for Dificid...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news